Research Article: Resources available for parent-provider vaccine communication in pregnancy in Canada: a scoping review
Abstract:
Objective Vaccination in pregnancy (VIP) is a protective measure for pregnant individuals and their babies. Healthcare provider’s (HCP) recommendations are important in promoting VIP. However, a lack of strong recommendations and accessible resources to facilitate communication impact uptake. This study sought to determine the extent of and characterise the resources available for parent-provider vaccine communication in pregnancy in Canada using a behavioural theory-informed approach. Design Scoping review. Methods In accordance with the JBI methodology, nine disciplinary and interdisciplinary databases were searched, and a systematic grey literature search was conducted in March and January 2022, respectively. Eligible studies included resources available to HCPs practising in Canada when discussing VIP, and resources tailored to pregnant individuals. Two reviewers piloted a representative sample of published and grey literature using inclusion-exclusion criteria and the Authority, Accuracy, Coverage, Objectivity, Date, Significance guidelines (for grey literature only). Sixty-five published articles and 1079 grey reports were screened for eligibility, of which 19 articles and 166 reports were included, respectively. Results From the 19 published literature articles and 166 grey literature reports, 95% were driven by the ‘Knowledge’ domain of the Theoretical Domains Framework, while n=34 (18%) addressed the ‘Skills’ domain. Other gaps included a lack of VIP-specific tools to address hesitancy and a lack of information on culturally safe counselling practices. Conclusion The study suggests a need for resources in Canada to improve VIP communication skills and improve access to vaccination information for HCPs and pregnant individuals. The absence of such resources may hinder VIP uptake.
Introduction:
The Canadian National Advisory Committee on Immunization (NACI) recommended that all pregnant individuals receive the inactivated influenza vaccine, 1 the tetanus-diphtheria-acellular pertussis (Tdap) vaccine 2 and the COVID-19 3 vaccine since 2007, 2018 and 2021, respectively. These vaccines are effective at preventing maternal and/or neonatal mortality and morbidity, 3 4 and are safe for use during pregnancy. 3 5 Despite these recommendations, many pregnant individuals struggle with their decision to vaccinate…
Read more